And in studies conducted on another popular weight loss drug called terzepatide (aka, Mounjaro), 5.7 percent of patients reported experiencing hair loss versus less than 1 percent on a placebo
Allowing for metabolic shifts
Eligibility for weight loss treatment typically requires a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or obstructive sleep apnea
Learn which medication might align best with your specific health priorities and how to discuss these options with your healthcare provider
If GLP-1 use increases and it is expected to with a new pill format being introduced McConnell expects to see a decrease in traffic across the food-away-from home ecosystem, including quick-service restaurants, fine dining, fast casual and even nightclubs
We have a real brick and mortar office where we see patients, we arent an unknown provider on the internet